Oritavancin: A new promising agent in the treatment of infections due to Gram-positive pathogens

Expert Opinion on Investigational Drugs

Volumn 17, Issue 2, 2008, Pages 225-243

  Poulakou, Garyphallia ^a   Giamarellou, Helen ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Drug resistant Streptococcus pneumoniae; Glycopeptide resistant cocci; MRSA; Multi drug resistant pathogens; New antibiotics; Oritavancin; VISA GISA; VRE

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFALEXIN; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DALBAVANCIN; DAPTOMYCIN; DECHLOROEREMOMYCIN; DEXAMETHASONE; DICLOXACILLIN; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; METRONIDAZOLE; ORITAVANCIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; PPI 0903; PPI 0903M; STREPTOGRAMIN DERIVATIVE; TAK 599; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; GLYCOPEPTIDE;

ABSCESS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BIOFILM; BLOOD TOXICITY; BONE MARROW TOXICITY; CATHETER INFECTION; CLINICAL TRIAL; CLOSTRIDIA; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EDEMA; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; HYPOKALEMIA; HYPOTENSION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INJECTION SITE THROMBOSIS; KIDNEY DYSFUNCTION; LIPIDOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE SPASM; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NEURITIS; OTOTOXICITY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHLEBITIS; POSTANTIBIOTIC EFFECT; PROTEIN SYNTHESIS INHIBITION; QT PROLONGATION; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STAPHYLOCOCCUS; STREPTOCOCCUS; STRUCTURE ANALYSIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREMOR; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING; ANIMAL; DRUG EFFECT; MICROBIOLOGY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 39049155534     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.2.225     Document Type: Article

References (156)

1. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews. Available at: URL: idsociety.org/ [Accessed 30 September, 2007]
2. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42(5):657-68
3. Hoffman-Roberts HL, E CB, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin Investig Drugs 2005;14(8):973-95
4. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2603;31(8):481-98
5. Rosenthal VD, Maid DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006;145(8):582-91
6. Lindsay JA, Holden MT. Staphylococcus aureus: superbug, super genome? Trends Microbiol 2004;12(8):378-85
7. Naimi TS, Ledell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290(22):2976-84.
8. Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 2006;12(Suppl 1):9-15
9. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007;45(6):1705-11
10. Ledercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319(3):157-61
11. Uttley AH, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103(1):173-81
12. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46(35):813-5
13. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46(27):624-6
14. Torres-Viera C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr Opin Infect Dis 2004;17(6):541-7
15. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Ann Rev Microbiol 2002;56:657-75
16. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006;12(Suppl 1):16-23
17. Sancak B, Ercis S, Menemenhoglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005;56(3):519-23
18. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;39(4):539-45
19. Anonymous: Centers for Disease Control and Prevention, 2002. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Morb Mortal Wkly Rep 2002;(51):902
20. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007;51(1):231-8
21. Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal. Wkly Rep 2004;53(15):322-3
22. Anonymous: Centers for Disease Control and Prevention, 2002. Staphylococcus aureus resistant to vancomycin - United States. Morb Mortal Wkly Rep 2002;(51):565-7
23. Anonymous: Centers for Disease Control and Prevention, 2004. Brief report: vancomycin-resistant Staphylococcus aureus - New York, 2004. Morb Mortal Wkly Rep 2004;(53):322-33
24. An updated health website, citing the six currently reported case (patients), harboring seven distinct VRSA strains in USA. Available at: URL://www.odh. ohio.gov/pdf/IDCM/staph.pdf [Accessed September 29, 2007]
25. Uttley AH, Woodford N, Johnson AP, Cookson B, George RC. Vancomycin-resistant enterococci. Lancet 1993;342(8871):615; author reply 616
26. Targanta homepage: Information relevant to oritavancin development status. Available at: URL: www.targanta.com/ [Accessed September 30, 2007]
27. Ward KE, Mersfelder TL, Laplante KL. Oritavancin - an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006;15(4):417-29
28. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006;6(5):486-90.
29. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357(9263):1179
30. Roberts SM, Freeman AF, Harrington SM, et al. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006;25(6):562-4
31. FDA homepage, FDA Alert issued 16/3/2007 on linezolid. Available at: URL: www.fda.gov/cder/drug/InfoSheets/HCP/ linezolidHCP.htm [Accessed January 2008]
32. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34(5):695-8
33. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46(8):2723-6
34. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4(8):528-31
35. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42(11):1578-83
36. Noskin GA. Tigecycline; a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
37. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003;52(1):138-9
38. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004;49(3):201-9
39. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-67
40. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
41. Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin Investig Drugs 2007;16(2):137-55
42. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(8):2538-44
43. Johnson AP, Mushtaq S, Warner M, Livermore DM. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents 2004;24(4):315-9
44. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006;28(5):385-8
45. Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;26(5):619-26
46. Laplante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48(12);4665-72
47. Echevarria K, Datta P. Cadena J, Lewis JS II. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005;55(4):599-600
48. Arbeit RD, Maki D, Tally FP, Campanaro, E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81
49. Dvorchik BH, Brazier D, Debruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47(4):1318-23
50. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
51. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient With acute myeloid leukemia. Mayo Clin Proc 2005;80(9):1215-6
52. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(3):1079-82
53. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191(12):2149-52
54. Dalbavancin: Treatment for Skin and Structure Infection. Available at: URL: www.drugs.com/nda/dalbavancin_050511.html [Accessed November 20, 2007]
55. http://www.pfizer.com/ Pfizer website (assessed: September 30, 2007)
56. Bozdogan B, Ednie L, Credito K, Kosowska K, Appelbaum PC. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004;48(12):4762-5
57. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003;52(5):864-8
58. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005;49(2):770-2
59. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In-vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999;44(2):179-92
60. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004;48(3):940-5
61. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005;55(Suppl 2):1125-30
62. Dowell J, Seltzer E, Buckwalter M, Marbury T. The pharmacokinetics of dalbavancin (DAL) in subjects with mild, moderate or severe hepatic impairment (HI). 44th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC; 30 October - 2 November, 2004. Poster A-19
63. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41(10):1407-15
64. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40(3):374-80
65. Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect 2005;50(3):206-9
66. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006;58(3):627-31
67. Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007;51(4):1150-4
68. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 2006;26(7):908-18
69. Theravance homepage: information relevant to telavancin development status. Available at: URL: www.theravance.com/ [Accessed September 30, 2007]
70. Astellas homepage: information relevant to telavancin development status. Available at: URL: www.astellas.com/ [Accessed September 30, 2007]
71. Telavancin: TD 6424, TD-6424. Drugs R&D 2006;7(6):384-8
72. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci - Eur J Clin Microbiol Infect Dis; 2007
73. King A. Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004;53(5):797-803
74. Shaw JP, Seroogy J, Kaniga K et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201
75. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilin model. J Antimicrob Chemother 2005;56(2):337-43
76. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40(11):1601-7
77. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-7
78. Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44(7):689-95
79. Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis 2004;50(1):73-5
80. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002;50(6):915-32
81. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against steptococci, enteroccoci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003;9(11):1120-4
82. Bush K. Heep M. Macielag MI. Noel GI. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first and-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007;16(4):419-29
83. Noel GJ, Strauss RS, Amsler K, et al. Treatment of complicated skin and skin structure infections caused by Gram-positive bacteria with ceftobiprole: results of a double-blind, randomized trial. Antimicrob Agents Chemother; 2007;52(1):37-44.
84. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49(10):4210-9
85. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45(Suppl 3):S184-90
86. Johnson and Johnson homepage Pharmaceutical Pipeline PDF, as of July 17, 2007 presenting development status of ceftobiprole. Available at: URL: jnj.com/ [Accessed September 30, 2007]
87. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49(8):3501-12
88. Homepage of Cerexa, providing information on ceftaroline. Available at: URL: www.cerexa.com/products.html [Accessed September 30, 2007]
89. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51(9):3397-400
90. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60(2):300-11
91. Talbot GH, Thye D, Das A, Ge Y. Phase II study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51(10):3612-6
92. Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56(6):1047-52
93. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50(4):1376-83
94. Homepage of Forest Laboratories providing information on ceftatoline. Available at: URL: www.frx.com/research/pipeline.aspx [Accessed September 30, 2007]
95. The link of the official trial registration database of NIH. Available at: URL: clinicaltrials-nccs.nlm.nih.gov/ct2/results?term= ceftaroline+and+infection [Accessed November 20, 2007]
96. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003;26(5):511-32
97. Malabarba A, Ciabatti R, Kettenring J, et al. Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity. J Antibiot (Tokyo) 1994;47(12):1493-506
98. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004;64(9):913-36
99. Lehoux D, Okusanya OO, Laquerre K, et al. PK-PD of oritavancin (ORI) against Streptococcus pneumoniae (SP) in a murine-pneumonia infection model. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster A-49
100. Arhin F, Sarmiento I, Parr TR Jr, Moeck G. Mechanisms of action of oritavancin in Staphylococcus aureus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster C1-1471
101. Belley A, Harris B, Beveridge T, Parr TR Jr, Moeck G. Differential targeting of cell wall assembly systems by oritavancin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster C1-1472
102. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003;111(9):1265-73
103. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000;44(9):2276-85
104. Sieradzki K, Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 2003;185(24):7103-10
105. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist 2001;7(3):229-36
106. Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005;49(1):470-2
107. Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999;43(8):1875-80
108. Lefort A, Saleh-Mghir A, Garry L, Carbon C, Fantin B. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or-resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000;44(11):3017-21
109. Arhin F, Sarmiento I, Parr TR Jr, Moeck G. Effect of polysorbate-80 on oritavancin binding to plastic surface-implications for susceptibility testing. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany; 2007. Poster-1112
110. Arhin F, Sarmiento I, Belley A, Mckay GA, Parr TR Jr, Moeck G. Activity of oritavancin against drug-resistant Staphylococcus aureus in the presence of polysorbate-80. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster D-242
111. Draghi D, Moeck G, Thornsberry C, Sahm DF. Comparative in vitro potency of oritavancin (ORI), teicoplanin (TEI), and vancomycin (VAN) against glycopeptide-susceptible and -resistant gram-positive organisms. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-721
112. Draghi D, Sahm DF, Arhin FF, Moeck G. Anti-enterococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against gram-positive infections. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1615
113. Draghi D, Moeck G, Arhin FF, Sahm DF. Anti-streptococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against gram-positive infections. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E1616
114. Grover P, Draghi DC, Moeck G, Arhin FF, Sahm DF. In vitro activity profile of oritavancin (ORI) against organisms demonstrating key resistance profiles to other antimicrobial agents. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1613
115. Sahm D, Moeck G, Arhin FF, Draghi DC. In vitro activity profile of oritavancin against resistant staphylococcal populations from a recent surveillance initiative. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1617
116. Garcia-Garrote F, Cercenado E, Alcala L, Bouza E. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. Antimicrob Agents Chemother 1998;42(9):2452-5
117. Zeckel ML, Preston DA, Allen BS. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob Agents Chemother 2000;44(5):1370-4
118. Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 2000;44(11):2991-8
119. Baltch AL, Smith RP, Ritz WJ, Bopp LH. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
120. Biavasco F, Vignaroli C, Lupidi R, et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997,41(10):2165-72
121. Noviello S, Ianniello F, Esposito S. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J Antimicrob Chemother 2001;48(2):283-6
122. Schwalbe RS, Mcintosh AC, Qaivumi S. et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996;40(10):2416-9
123. Harland S, Tebbs SE, Elliott TS. Evaluation of thein vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J Antimicrob Chemother 1998;41(2):273-6
124. Jones RN, Barrett MS, Erwin ME. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997;41(2):488-93
125. Sillerstrom E, Wahlund E, Nord CE. In vitro activity of LY 333328 against anaerobic gram-positive bacteria. J Chemother 1999;11(2):90-2
126. Moeck G, Draghi DC, Arhin FF, Sahm DF. In vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1612
127. O'Connor R, Freeman J, Baines S, Wilcox M. In vitro susceptibility of genotypically distinct clostridium difficile strains to oritavancin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1618
128. Boylan CJ, Campanale K, Iversen PW, et al. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003;47(5):1700-6
129. Mercier RC, Houlihan HH, Rybal MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother 1997;41(6):1307-12
130. Van Bambeke F, Carryn S, Seral C, et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004;48(8):2853-60
131. Patel R, Rouse MS, Piper KE, Cockerill FR III, Steckelberg JM. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumonziae. Diagn Microbiol Infect Dis 1998;30(2):89-92
132. Fasola E, Spangler SK, Ednie LM, et al. Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996;40(11):2661-3
133. Saribas S, Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy 2004;50(5):250-4
134. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006;42(Suppl 1):S40-50
135. Zelenitsky SA, Karlowsky JA, Zhanel GG, Hoban DJ, Nicas T. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Antimicrob Agents Chemother 1997;41(6):1407-8
136. Mckay G, Beaulieu S, Belley A, Arhin FF, Parr TR Jr, Moeck G. In vitro time kill studies of oritavancin against drug-resistant isolates of Staphylococcus aureus and enterococci. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1614
137. Mckay G, Beaulieu S, Parr TR Jr, Moeck G. In vitro post antibiotic effect studies of oritavancin against Staphylococcus aureus and enterococci. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster A-50
138. Belley A, Mckay GA, Fadhil I, Beaulieu S, Moeck G, Parr TR Jr. Oritavancin kills Staphylococcus aureus in slow-growing planktonic and biofilm states. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. Poster B-661
139. Belley A, Neesham-Grenon E, Parr TR Jr, Moeck G. E-1620 Pharmacokinetic concentrations of oritavancin kill stationary-phase and biofilm staphylococcus aureus in vitro. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Poster E-1620
140. Belley A, Neesham-Grenon E, Beaulieu S, et al. Synergistic effects of oritavancin tested in combination with other agents. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster E-1619
141. Bhavnani S, Rubino CM, Forrest A, et al. Use of pharmacokinetic-pharmacodynamic (PK-PD) principles to guide clinical drug development for oritavancin (ORI). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2007. Poster A-51
142. Owen JS, Bhavnani SM, Fielder-Kelly J, Loutit JS, Porter SB. Population pharmacokinetics of oritavancin. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA; 2004. Poster A-20
143. Chien J, Allerheiligen S, Philips DL, Cerimele B, Thomasson HR. Safety and pharmacikinetics of single intravenous doses of LY333328 diphosphonate (glycopeptide) in healthy men. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA; 1998. Poster A-55
144. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004;50(2):95-102
145. Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005;49(1):148-52
146. Gerber J, Smirnov A, Wellmer A, et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001;45(7):2169-72
147. Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1999;43(1):115-20
148. Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens PM. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother 2005;49(5):1695-700
149. Al-Nawas B, Swantes J, Shah PM. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci. Infection 2000;28(4):214-8
150. Rupp ME, Fey PD, Longo GM. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother 2001;47(5):705-7
151. Cabellos C, Fernandez A, Maiques JM, et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2003;47(6):1907-11
152. Kaatz GW, Seo SM, Aeschlimann JR, et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998;42(4):981-3
153. Lehoux D, Arhin FF, Fadil I, et al. Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphylococcus aureus infection. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. Poster B-404
154. Wasilewski M, Disch D, Mcgill J, Harris H, O'Riordan W, Zeckel ML. Equivalence of shorter course therapy with oritavancin compared to vancomycin/cephalexin in complicated skin/skin structure infections. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 2001. Poster UL-18.
155. Giamarellou H, O'Riordan W, Harris H, Porter S, Loutit J. Phase III trial comparing 3 - 7 days of oritavancin versus 10 - 14 days of vancomycin/cephalexin in the treatment of patients with complicated skin/ skin structure infections (CSSI). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA; 2003. Poster L-739a
156. Niederman MS. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care 2006;12(5):452-7